1. Molecular Immunology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione Istituti di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori, Milan, Italy;
2. Department of Human Pathology, University of Palermo, Palermo, Italy;
3. Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione Istituti di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori, Milan, Italy; and
4. Dynavax Technologies Corporation, Berkeley, CA